Abstract
When 99mTc was first applied to radiopharmaceuticals for diagnostic nuclear medicine, major efforts were focused on the development of 99mTc complexes for excretory organs such as the liver and kidney. Over the past 30 years, a significant advance was made in technetium chemistry and radiopharmaceutical design. Now, 99mTc radiopharmaceuticals for measuring regional cerebral and myocardial blood flow are available in clinical studies. More recently, transporter functions of the brain can also be visualized with 99mTc radiopharmaceuticals. In this manuscript, recent advances in 99mTc radiopharmaceuticals will be briefly reviewed.
